Ala'Aldeen D A
Division of Microbiology, Department of Clinical Laboratory Sciences, University Hospital, Queen's Medical Centre, Nottingham, UK.
J Med Microbiol. 1996 Apr;44(4):237-43. doi: 10.1099/00222615-44-4-237.
Production of a meningococcal vaccine capable of generating long-lasting immunity in all age groups is still a high priority worldwide. Iron-regulated outer-membrane proteins have attracted considerable attention in recent years and it has become increasingly evident that the meningococcal transferrin-binding proteins, TBP1 and TBP2, have characteristics compatible with a safe and broadly cross-reactive vaccine candidate. Both TBPs are surface-exposed and immunogenic in man and animals, and antibodies to their native structure are bactericidal to homologous and many heterologous strains. These include strains from various serogroups, serotypes and serosubtypes, with no obvious correlation between bactericidal activity and the identity of the strains or the molecular mass of the heterogeneous TBP2 molecule. A meningococcal vaccine based on, or enriched with, undenatured TBPs from one or more strains, in combination with conventional polysaccharide-based vaccines, might increase the spectrum of strains against which protection can be achieved to include serogroup B strains. In this review, the structure-function and immunological properties of TBP1 and TBP2 are discussed.
生产一种能够在所有年龄组中产生持久免疫力的脑膜炎球菌疫苗仍然是全球的一项高度优先事项。近年来，铁调节外膜蛋白引起了相当大的关注，越来越明显的是，脑膜炎球菌转铁蛋白结合蛋白TBP1和TBP2具有与安全且广泛交叉反应的候选疫苗相容的特性。两种TBP均暴露于表面且在人和动物中具有免疫原性，针对其天然结构的抗体对同源和许多异源菌株具有杀菌作用。这些菌株包括来自各种血清群、血清型和血清亚型的菌株，杀菌活性与菌株的身份或异质TBP2分子的分子量之间没有明显的相关性。基于一种或多种菌株的未变性TBP或富含未变性TBP的脑膜炎球菌疫苗，与传统的基于多糖的疫苗联合使用，可能会扩大可实现保护的菌株范围，包括B血清群菌株。在这篇综述中，讨论了TBP1和TBP2的结构功能和免疫学特性。
